Two Kidney Week 2026 posters suggest remnant cholesterol–based markers may help stratify CKD severity and cardiovascular death risk on hemodialysis.
|Videos|May 21, 2021
The Future of Lengthening the Patient Lifecycle and Further Developing Pharmacy Services
Pharmacy Times spoke with Lauren Simko, managing performance specialist at Pharmacy Development Services, about the future of lengthening the patient lifecycle and further developing pharmacy services.
Advertisement
Pharmacy Times spoke with Lauren Simko, managing performance specialist at Pharmacy Development Services, about the future of lengthening the patient lifecycle and further developing pharmacy services.
Simko discussed how patients need more and pharmacies need more than the typical revenue streams.
Advertisement
Related to this article
A pharmacy technician reflects on 3 patient encounters that reshaped his
understanding of what a real patient requires.
CDC surveillance data show that approximately 10% of adults hospitalized with RSV died during hospitalization or within 60 days of discharge.
VAX-31 met all primary immunogenicity end points against PCV20 and PCV21 in the pivotal OPUS-1 trial.
Expert Q&A: Geisinger Investigator Discusses Low Flu Vaccination Rates, ICU Findings in Older Adults
A study author explains how pharmacists can help close vaccination gaps in rural communities and what lower ICU admission rates among vaccinated older adults may mean.
From AKI dosing to CKM therapeutic inertia, experts at ASN Kidney Week 2026 pointed to pharmacists as key to moving new kidney data into practice.
Kidney Week 2026 posters show low-density lipoprotein cholesterol (LDL-C) fell by half in patients receiving dialysis, and oral enlicitide needed no dose adjustment for renal impairment.
Joshua J. Neumiller, PharmD, CDCES, of the American Diabetes Association, discusses pharmacists’ role in diabetes and CKD care at ASN Kidney Week 2026.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Community Pharmacists Guide Patients New to Glucose Monitoring
2
FDA Approves Tildrakizumab for Adults With Psoriatic Arthritis
3
Early Nirmatrelvir/Ritonavir Linked to Lower Long COVID Risk in High-Risk Outpatients
4
Narrow Therapeutic Index Chemotherapy Dosing With eGFR: Safeguards for Oncology Pharmacists
5